FOLH1 and neoplasm: The follow-up PET imaging with [68Ga]Ga-PSMA-617 showed a significantly greater tumor uptake reduction within a month in the treatment group of [177Lu]Lu-EB-PSMA-617 than in that of [177Lu]Lu-PSMA-617 (SUV change: −32.43  ±  0.14% vs. 0.21  ±  0.37%; p  =  0.002).